Autres langues HLS Therapeutics Inc.

Actions

HLS

CA40390B1094

Temps Différé Toronto S.E. Autres places de cotation 16:33:18 27/06/2024			Varia. 5j.	Varia. 1 janv.
3,29 ^CAD	-2,08 %		-4,36 %	-16,71 %

07/06	Transcript : HLS Therapeutics Inc. - Shareholder/Analyst Call
28/05	HLS Therapeutics Inc. annonce la publication d'une nouvelle étude sur l'impact des programmes de soutien pharmaceutique sur la persistance du traitement à la clozapine	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

HLS Therapeutics Reports Annual Meeting Results	08/06
HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study	28/05
New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment	28/05
HLS Therapeutics Inc. Announces New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment	28/05
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance	09/05
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 9, 2023.	09/05
HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
HLS Therapeutics Brief: Q1 2024 revenue was US$12.5 million, Adjusted EBITDA was $2.7 million and cash from operations was $0.8 million	09/05
HLS Therapeutics Announces Q1 2024 Financial Results	09/05
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024	09/05
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call	25/04
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 9, 2023.	12/04
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 10, 2022.	12/04
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA	08/04
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	08/04
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update	14/03
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022	14/03
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million	14/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues HLS Therapeutics Inc.

Actions

HLS

CA40390B1094

Autres langues

Filtres